Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lexicon Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
LXRX
Nasdaq
2834
https://www.lexpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals to Host 2024 Investor Day
- Apr 18th, 2024 12:00 pm
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
- Apr 16th, 2024 4:00 pm
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Apr 3rd, 2024 12:00 pm
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
- Mar 25th, 2024 1:20 pm
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
- Mar 13th, 2024 4:45 pm
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
- Mar 12th, 2024 12:00 pm
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
- Mar 11th, 2024 12:25 pm
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
- Mar 11th, 2024 11:15 am
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
- Mar 11th, 2024 11:05 am
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
- Mar 11th, 2024 11:00 am
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
- Feb 29th, 2024 3:00 pm
15 Hot Penny Stocks On the Move
- Feb 22nd, 2024 5:58 pm
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
- Jan 31st, 2024 10:06 am
3 of the Fastest-Growing Stocks on the Planet in 2024
- Jan 23rd, 2024 10:21 am
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 24%
- Jan 11th, 2024 1:28 pm
Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 8th, 2024 12:00 pm
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
- Dec 26th, 2023 10:06 am
Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
- Dec 21st, 2023 9:15 pm
MSCLF: AAK1 Disclosed as Drug Target for DMD Program…
- Dec 13th, 2023 2:46 pm
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
- Nov 30th, 2023 12:30 pm
Scroll